India The Indian pharma market clocked up double-digit growth of around 15 percent in 2021 (compared to three percent in 2020), driven primarily – but not only – by products related to COVID-19. Local companies performed well thanks to strong domestic demand and several, such as the five listed below, grew…
Top 5 In 2019 PharmaBoardroom had the exclusive opportunity to speak with executives that are heading up some of European pharma’s top companies. These stakeholders provided insights into their visions and strategies for success and how they are embracing innovation as they forge ahead. David Loew, Executive Vice President, Sanofi…
China China-born entrepreneurs are returning to their homeland to find an industry filled with incentives in place for innovation, independent of generics. Here, we highlight five unique biotechs looking to serve the unmet needs of patients with their cutting-edge technologies in cardiology, immunology and more. Adagene Adagene’s founder and CEO…
China Earlier this year, PharmaBoardroom highlighted five of the most innovative and important biotech companies making waves in the world’s second-largest pharmaceutical market, China. Here, we pick out five more firms looking to crack both the Chinese and international markets. EpimAB Biotherapeutics Founded in 2015, EpimAb Biotherapeutics is a privately owned…
China Even though China’s pharmaceutical sector remains largely generics-based, the Middle Kingdom’s biotechnology scene has been flourishing in recent years. Now the world’s fastest-growing biopharmaceutical market, China can boast a much-improved context in terms of drug regulation, ease of doing business, research capabilities and access to capital. Below, we highlight 5…
Spain Spain’s biotech scene is on the rise. In 2016 alone, the nation had a total of 651 biotech companies, with a total of 33 commencing operations in 2017. Despite these quite modest numbers in comparison to more well-established global biotech hubs, they have been accompanied by some extremely encouraging exits.…
biotech Local flagship company Boryung has found success with its newly developed angiotension receptor blocker (ARB) Kanarb. Nine molecules currently exist worldwide in this category of antihypertensives, and Kanarb is currently ranked eighth. “Boryung is the only domestic company that has developed a drug from start to finish, including outlicensing. Of…
See our Cookie Privacy Policy Here